Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

Valganciclovir for cytomegalovirus preemptive therapy in patients following allogeneic hematopoietic stem cell transplantation

Objective and;To evaluate the clinical value of valganciclovir in preemptive treatment of cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT) by comparing the efficacy of the drug with other conventional antiviral drugs (ganciclovir or foscarnet sodiu...

Full description

Bibliographic Details
Main Authors:	LU Xuan, YAN Han, XIA Linghui
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of Third Military Medical University 2020-09-01
Series:	Di-san junyi daxue xuebao
Subjects:	cytomegalovirus viremia allogeneic hematopoietic stem cell transplantation valganciclovir preemptive therapy antithymocyte globulin
Online Access:	http://aammt.tmmu.edu.cn/Upload/rhtml/202005126.htm

Similar Items

Efficacy of Low Dose Valganciclovir Prophylaxis for Cytomegalovirus Infection in Kidney Transplantation
by: Ümit Özçelik, et al.
Published: (2020-01-01)

Comparison of prophylactic versus preemptive treatments in the management of cytomegalovirus infection in renal transplant recipients
by: Cengiz Karaçin, et al.
Published: (2020-05-01)

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia
by: Arindam Singha, et al.
Published: (2021-04-01)

The use of allogeneic bone marrow transplantation and immunosuppressive therapy in the treatment of patients with acquired aplastic anemia
by: A A Ganapiyev, et al.
Published: (2010-07-01)

Refractory ulcerative colitis complicated by cytomegalovirus infection successfully treated with valganciclovir
by: Tiziana Larussa, et al.
Published: (2012-11-01)

Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis
by: Siavash Vaziri, et al.
Published: (2014-01-01)

Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature
by: Donglin Yang, et al.
Published: (2023-12-01)

Cytomegalovirus mismatch after heart transplantation: Impact of antiviral prophylaxis and intravenous hyperimmune globulin
by: Moritz B. Immohr, et al.
Published: (2021-12-01)

Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation
by: Ian Pang, et al.
Published: (2022-01-01)

Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial
by: Tomas Reischig, et al.
Published: (2018-11-01)

The Ten Most Common Questions on Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Patients
by: Johnny Zakhour, et al.
Published: (2022-12-01)

Monitoring of resistanceassociated mutations in UL97 gene of cytomegalovirus in children after allogeneic hematopoietic stem cell transplantation
by: Kozhushnaya O.S., et al.
Published: (2022-03-01)

Role of oral valganciclovir in sick preterm with cytomegalovirus virus infection and ventilation dependence
by: Anumodan Gupta, et al.
Published: (2019-01-01)

Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children’s patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study
by: Yongsheng Ruan, et al.
Published: (2022-10-01)

Mutations in the cytomegalovirus UL97 gene associated with ganciclovir resistance in recipients of allogeneic hematopoietic stem cell transplants
by: Demin M.V., et al.
Published: (2019-12-01)

Role of antithymocyte globulin in reducing the incidence of complications after allogeneic hemopoietic cell transplantation
by: Yu R Zalyalov, et al.
Published: (2010-08-01)

Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation
by: Taeyun Kim, et al.
Published: (2020-03-01)

The state of the art in the treatment of severe aplastic anemia: immunotherapy and hematopoietic cell transplantation in children and adults
by: Agnieszka Piekarska, et al.
Published: (2024-04-01)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
by: Giuseppe Stragliotto, et al.
Published: (2020-09-01)

Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
by: Shuang Fan, et al.
Published: (2022-01-01)

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
by: Xuan Li, et al.
Published: (2012-08-01)

Cytomegalovirus Infection in Kidney Transplant Recipients
by: Dino Šisl, et al.
Published: (2021-04-01)

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study
by: Dukhee Nho, et al.
Published: (2023-09-01)

Cytomegalovirus Infection and Treatment in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study from a Single Institution in an Endemic Area
by: Hsin - Chen Lin, et al.
Published: (2017-05-01)

Differential Interaction of Peripheral Blood Lymphocyte Counts (ALC) With Different in vivo Depletion Strategies in Predicting Outcomes of Allogeneic Transplant: An International 2 Center Experience
by: Vipul Sheth, et al.
Published: (2019-07-01)

Patient risk stratification and tailored clinical management of post‐transplant CMV‐, EBV‐, and BKV‐infections by monitoring virus‐specific T‐cell immunity
by: Anastasia Papadopoulou, et al.
Published: (2021-08-01)

Valganciclovir as Add-on to Second-Line Therapy in Patients with Recurrent Glioblastoma
by: Mattia Russel Pantalone, et al.
Published: (2022-04-01)

Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review
by: Bruno Mendes, et al.
Published: (2022-08-01)

Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients
by: Dominika Deborska-Materkowska, et al.
Published: (2018-04-01)

The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
by: Masoud Mardani, et al.
Published: (2020-12-01)

Revisit of the Association between Cytomegalovirus Infection and Invasive Fungal Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Real-World Analysis from a High CMV Seroprevalence Area
by: Tsung-Jang Yeh, et al.
Published: (2022-04-01)

Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis
by: Martyna Wlodarczyk, et al.
Published: (2024-03-01)

Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study
by: Chunrong Ju, et al.
Published: (2022-11-01)

Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?: A systematic review and meta-analysis
by: Dipesh Kumar Yadav, et al.
Published: (2022-11-01)

Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications
by: G. R. Pourmand, et al.
Published: (2012-04-01)

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review
by: El Helou G, et al.
Published: (2019-06-01)

Hidrops fetal por infección congénita por citomegalovirus: tratamiento posneonatal prolongado con valganciclovir
by: Silvia Campos Arca, et al.
Published: (2012-01-01)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
by: Delaney Wolfe, et al.
Published: (2021-11-01)

Risk factors of CMV replication after allogeneic hematopoietic stem cell transplantation in children and adolescents
by: S. N. Shiriaev, et al.
Published: (2014-09-01)

Risk factors of CMV replication after allogeneic hematopoietic stem cell transplantation in children and adolescents
by: S. N. Shiriaev, et al.
Published: (2014-09-01)